Outbound Deals - SinoDrugWatch

HRS-1893

Hengrui Out-Licenses HRS-1893: Structure, Patent & Global Race with Aficamten and Mavacamten

Hengrui’s HRS-1893, out-licensed to Braveheart Bio, enters the global oHCM race with aficamten and mavacamten. ESC 2025 Phase I showed safety and PK; Phase III (NCT07021976) is ongoing. This review covers HRS-1893 chemical structure, patents, preclinical PK, and trial data.

Outbound Deals

China’s $60B Out-Licensing Boom in 2025 Positions Biotech as Global Powerhouse in Oncology & Obesity

Chinese biopharmas may reach ~$60B in outbound deals by end-2025, led by Hengrui–GSK, 3SBio–Pfizer, XtalPi–DoveTree, and Hansoh–Regeneron. Oncology, obesity, and AI fuel China’s rise as a global licensing powerhouse, with top deals and trends highlighted.

Outbound Deals

China’s Biotech Boom: Top Outbound Deals Signal Global Innovation Leadership

Witness the new era of global biotech collaboration as China's top outbound deals inject billions into innovation. From 3SBio's $1.25B Pfizer licensing to BioNTech's acquisition of Biotheus, explore key themes in bispecifics, ADCs, and strategic partnerships.